These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33997096)

  • 1. Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment.
    Pierzchlewicz K; Kępa I; Podogrodzki J; Kotulska K
    Child Neurol Open; 2021; 8():2329048X211008725. PubMed ID: 33997096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risdiplam for the treatment of spinal muscular atrophy].
    Vlodavets DV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):45-57. PubMed ID: 38465810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I.
    Mirea A; Shelby ES; Axente M; Badina M; Padure L; Leanca M; Dima V; Sporea C
    J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy.
    Kotulska K; Fattal-Valevski A; Haberlova J
    Front Neurol; 2021; 12():726468. PubMed ID: 34721262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selecting disease-modifying medications in 5q spinal muscular atrophy.
    Cartwright MS; Upadhya S
    Muscle Nerve; 2021 Oct; 64(4):404-412. PubMed ID: 34231920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
    Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
    Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances and limitations for the treatment of spinal muscular atrophy.
    Day JW; Howell K; Place A; Long K; Rossello J; Kertesz N; Nomikos G
    BMC Pediatr; 2022 Nov; 22(1):632. PubMed ID: 36329412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy.
    Blair HA
    CNS Drugs; 2022 Sep; 36(9):995-1005. PubMed ID: 35960489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
    Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
    Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.
    Hjartarson HT; Nathorst-Böös K; Sejersen T
    Drug Des Devel Ther; 2022; 16():1865-1883. PubMed ID: 35734367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy.
    Naveed A; Calderon H
    J Pediatr Pharmacol Ther; 2021; 26(5):437-444. PubMed ID: 34239394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance.
    Keinath MC; Prior DE; Prior TW
    Appl Clin Genet; 2021; 14():11-25. PubMed ID: 33531827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies.
    Chiriboga CA
    Paediatr Drugs; 2022 Nov; 24(6):585-602. PubMed ID: 36028610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma).
    Ogbonmide T; Rathore R; Rangrej SB; Hutchinson S; Lewis M; Ojilere S; Carvalho V; Kelly I
    Cureus; 2023 Mar; 15(3):e36197. PubMed ID: 37065340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy.
    Li Y; Zeng H; Wei Y; Ma X; He Z
    Hum Gene Ther; 2023 Mar; 34(5-6):180-191. PubMed ID: 36762938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of Spinal Muscular Atrophy].
    Ishiyama A
    Brain Nerve; 2023 May; 75(5):507-510. PubMed ID: 37194521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug treatment for spinal muscular atrophy type I.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.